Search

Displaying results 4711 - 4720 of 6949 in total
  1. Drug

    Zeluvalimab

    go.drugbank.com/drugs/DB18868
    Investigational

    Zeluvalimab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (Mcrpc)).

  2. Drug

    PLT012

    go.drugbank.com/drugs/DB23610
    Investigational

    PLT012 is a humanized anti-CD36 antibody developed by Pilatus Biosciences for treating liver cancer and intrahepatic bile duct cancer.

  3. Drug

    PRX-07034

    go.drugbank.com/drugs/DB05993
    Experimental

  4. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    It is developed by MedImmune for the treatment of Allergic Rhinitis.

  5. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation

    Categories: Adenosine A2 Receptor Antagonists
  6. Drug

    Technetium Tc-99m arcitumomab

    go.drugbank.com/drugs/DB00113
    Experimental

    Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99.

  7. Drug

    IR501

    go.drugbank.com/drugs/DB06464
    Experimental

    IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity.

  8. Drug

    Ocaratuzumab

    go.drugbank.com/drugs/DB17359
    Investigational

    It is being investigated for cancers and autoimmune disorders.

  9. Drug

    TOL2

    go.drugbank.com/drugs/DB17918
    Experimental

    TOL2 is a modified form of the acetylcholine receptor being investigated for the treatment of myasthenia gravis.[A260117]

  10. Drug

    ISP-001

    go.drugbank.com/drugs/DB18501
    Investigational

    ISP-001 consists of sleeping beauty transposon-engineered autologous plasmablasts for expression and delivery of alpha-L-iduronidase.